Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Herpes Zoster 2Spondylitis, Ankylosing 1Psoriasis 1Osteosarcoma 1Neuroblastoma 1Crohn Disease 1Chickenpox 1Arthritis, Rheumatoid 1Arthritis, Psoriatic 1Arthritis 1

Interventions

Adalimumab 13Methotrexate 11Etanercept 10Rituximab 5Abatacept 5tocilizumab 4olokizumab 4tofacitinib 3golimumab 3Infliximab 3Tumor Necrosis Factor Inhibitors 2Saline Solution 2RC-18 2Nivolumab 2Leflunomide 2Certolizumab Pegol 2Antirheumatic Agents 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1entecavir 1cabozantinib 1baricitinib 1andecaliximab 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Arthritis, Rheumatoid × Herpes Zoster Vaccine × Clear all
NCT02538341 2021-11-23

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

University of Alabama at Birmingham

Phase 2 Completed
617 enrolled 17 charts

Arthritis, Arthritis, Rheumatoid, Crohn Disease, Psoriasis, Spondylitis, Ankylosing, Arthritis, Psoriatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡